Public Health Emergency - Leading a Nation Prepared
Monoclonal antibody therapeutics (mAb), including
casirivimab/imdevimab and bamlanivimab, can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized.
HHS/ASPR has purchased supplies of both COVID-19 monoclonal antibody therapeutic products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get casirivimab/imdevimab and bamlanivimab into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages